Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
C. Wang
Observed name:
Wang, C.
Institution:
Novartis (Switzerland)
Observed institution:
Novartis (Switzerland)
OpenAlex ID:
A5023908360
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
2021
·
D.J. Slamon
, P. Neven
, et al.
·
Annals of Oncology
·
310
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant
2023
·
P. Neven
, P. A. Fasching
, et al.
·
Breast Cancer Research
·
114
PDF
LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)
2022
·
P. Neven
, P.A. Fasching
, et al.
·
Annals of Oncology
·
12
Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’
2021
·
D.J. Slamon
, P. Neven
, et al.
·
Annals of Oncology
·
4
PDF
227P Ribociclib in early breast cancer: Drug-drug interaction and organ impairment assessments
2025
·
M. Untch
, F. Huth
, et al.
·
ESMO Open
·
1
228P Ribociclib (RIB) in early breast cancer (eBC): Pharmacokinetic (PK) assessment and exposure-response analysis
2025
·
J.P. Crown
, C. Wang
, et al.
·
ESMO Open
·
1
PDF
Show more works
View as search
Works count:
8
Citation count:
439
H-index:
4
I10-index:
3
Year
Topic
Type